Study with 3,334 patients validates circulating tumor DNA for genomic sequencing as an alternative to biopsies in mCRPC
The study demonstrated a high correlation between gene mutation changes identified by circulating tumor DNA (ctDNA) and biopsy-based genomic sequencing. In addition, liquid biopsies were better at identifying acquired resistance mechanisms than tissue biopsies.
Få tilgang til artikkelen
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in